Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy ...

Similar survival, GVHD rates with 7/8 or <7/8 HLA matching, with post-transplant cylophosp ...

Mesoblast Limited ( ($AU:MSB) ) has provided an update. An independent study presented at the American Society of Hematology Annual Meeting ...

A specific graft-versus-host disease prophylaxis regimen may expand allogeneic hematopoietic stem cell transplant access to ...

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...

A "hybrid" immune system approach may prevent or cure Type 1 diabetes (T1D) by combining blood stem cell and islet cell transplants. The method uses a nonmyeloablative conditioning regimen to prevent ...

A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure ...

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker. For many patients with blood ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...